Edition:
United Kingdom

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

259.84USD
21 Sep 2018
Change (% chg)

$2.06 (+0.80%)
Prev Close
$257.78
Open
$257.91
Day's High
$261.06
Day's Low
$255.79
Volume
323,408
Avg. Vol
110,163
52-wk High
$273.15
52-wk Low
$126.77

Select another date:

Fri, May 18 2018

BRIEF-Ligand Prices Offering Of $650 Mln Of Convertible Senior Notes

* LIGAND PRICES OFFERING OF $650 MILLION OF CONVERTIBLE SENIOR NOTES

BRIEF-Ligand Pharmaceuticals Announces Proposed Offering Of $650 Mln Of Convertible Senior Notes

* LIGAND ANNOUNCES PROPOSED OFFERING OF $650 MILLION OF CONVERTIBLE SENIOR NOTES

BRIEF-Ligand Pharmaceuticals Entered Commercial Platform License Agreement, With KSQ Therapeutics

* LIGAND PHARMACEUTICALS - ON MAY 8, ENTERED COMMERCIAL PLATFORM LICENSE AGREEMENT, WITH KSQ THERAPEUTICS, INC - SEC FILING

BRIEF-Ligand Reports Q1 Adjusted Earnings Per Share $1.55

* Q1 EARNINGS PER SHARE VIEW $1.15 -- THOMSON REUTERS I/B/E/S

BRIEF-Ligand Pharma Says Co Sent Computershare, As Rights Agent Under Glucagon CVR Agreement

* LIGAND PHARMACEUTICALS SAYS HOLDERS OF GLUCAGON CVRS ENTITLED TO RECEIVE PRO RATA $3.8 MILLION Source text: (https://bit.ly/2JHfcOF) Further company coverage:

BRIEF-Ligand Enters Into Agreement With venBio

* LIGAND ENTERS INTO AGREEMENT WITH VENBIO TO MAKE WORLDWIDE OMNIAB® PLATFORM LICENSE ACCESSIBLE TO PORTFOLIO COMPANIES Source text for Eikon: Further company coverage:

BRIEF-Ligand Pharmaceuticals Says ‍Entered Amendment No. 5 To Sublicense Agreement With Retrophin

* LIGAND PHARMACEUTICALS SAYS ‍ON MARCH 20, CO ENTERED INTO AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT, DATED FEB 16, 2012 WITH RETROPHIN, INC- SEC FILING​

Select another date: